186 related articles for article (PubMed ID: 12182958)
1. From cannabis to cannabinergics: new therapeutic opportunities.
Goutopoulos A; Makriyannis A
Pharmacol Ther; 2002 Aug; 95(2):103-17. PubMed ID: 12182958
[TBL] [Abstract][Full Text] [Related]
2. Cannabinergic ligands.
Palmer SL; Thakur GA; Makriyannis A
Chem Phys Lipids; 2002 Dec; 121(1-2):3-19. PubMed ID: 12505686
[TBL] [Abstract][Full Text] [Related]
3. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase.
Reggio PH; Traore H
Chem Phys Lipids; 2000 Nov; 108(1-2):15-35. PubMed ID: 11106780
[TBL] [Abstract][Full Text] [Related]
4. Oxygenated metabolites of anandamide and 2-arachidonoylglycerol: conformational analysis and interaction with cannabinoid receptors, membrane transporter, and fatty acid amide hydrolase.
van der Stelt M; van Kuik JA; Bari M; van Zadelhoff G; Leeflang BR; Veldink GA; Finazzi-Agrò A; Vliegenthart JF; Maccarrone M
J Med Chem; 2002 Aug; 45(17):3709-20. PubMed ID: 12166944
[TBL] [Abstract][Full Text] [Related]
5. Natural and synthetic endocannabinoids and their structure-activity relationships.
Palmer SL; Khanolkar AD; Makriyannis A
Curr Pharm Des; 2000 Sep; 6(13):1381-97. PubMed ID: 10903399
[TBL] [Abstract][Full Text] [Related]
6. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications.
Snider NT; Walker VJ; Hollenberg PF
Pharmacol Rev; 2010 Mar; 62(1):136-54. PubMed ID: 20133390
[TBL] [Abstract][Full Text] [Related]
7. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain.
Di Marzo V; Breivogel CS; Tao Q; Bridgen DT; Razdan RK; Zimmer AM; Zimmer A; Martin BR
J Neurochem; 2000 Dec; 75(6):2434-44. PubMed ID: 11080195
[TBL] [Abstract][Full Text] [Related]
8. Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol.
Hillard CJ
Prostaglandins Other Lipid Mediat; 2000 Apr; 61(1-2):3-18. PubMed ID: 10785538
[TBL] [Abstract][Full Text] [Related]
9. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo.
Bisogno T; Melck D; Bobrov MYu ; Gretskaya NM; Bezuglov VV; De Petrocellis L; Di Marzo V
Biochem J; 2000 Nov; 351 Pt 3(Pt 3):817-24. PubMed ID: 11042139
[TBL] [Abstract][Full Text] [Related]
10. The endocannabinoid system: physiology and pharmacology.
Rodríguez de Fonseca F; Del Arco I; Bermudez-Silva FJ; Bilbao A; Cippitelli A; Navarro M
Alcohol Alcohol; 2005; 40(1):2-14. PubMed ID: 15550444
[TBL] [Abstract][Full Text] [Related]
11. Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response.
De Petrocellis L; Melck D; Bisogno T; Milone A; Di Marzo V
Neuroscience; 1999; 92(1):377-87. PubMed ID: 10392859
[TBL] [Abstract][Full Text] [Related]
12. Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study.
Romero J; Hillard CJ; Calero M; Rábano A
Brain Res Mol Brain Res; 2002 Apr; 100(1-2):85-93. PubMed ID: 12008024
[TBL] [Abstract][Full Text] [Related]
13. Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors.
Reggio PH
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):143-60. PubMed ID: 12052032
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoids in the central nervous system--an overview.
Fride E
Prostaglandins Leukot Essent Fatty Acids; 2002; 66(2-3):221-33. PubMed ID: 12052038
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology.
Giuffrida A; Beltramo M; Piomelli D
J Pharmacol Exp Ther; 2001 Jul; 298(1):7-14. PubMed ID: 11408519
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase.
López-Rodríguez ML; Viso A; Ortega-Gutiérrez S; Fowler CJ; Tiger G; de Lago E; Fernández-Ruiz J; Ramos JA
J Med Chem; 2003 Apr; 46(8):1512-22. PubMed ID: 12672252
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships among N-arachidonylethanolamine (Anandamide) head group analogues for the anandamide transporter.
Jarrahian A; Manna S; Edgemond WS; Campbell WB; Hillard CJ
J Neurochem; 2000 Jun; 74(6):2597-606. PubMed ID: 10820223
[TBL] [Abstract][Full Text] [Related]
18. Biochemistry of the endogenous ligands of cannabinoid receptors.
Di Marzo V; Deutsch DG
Neurobiol Dis; 1998 Dec; 5(6 Pt B):386-404. PubMed ID: 9974173
[TBL] [Abstract][Full Text] [Related]
19. Novel selective and metabolically stable inhibitors of anandamide cellular uptake.
Ortar G; Ligresti A; De Petrocellis L; Morera E; Di Marzo V
Biochem Pharmacol; 2003 May; 65(9):1473-81. PubMed ID: 12732359
[TBL] [Abstract][Full Text] [Related]
20. Endocannabinoids: new targets for drug development.
Di Marzo ; Bisogno T; De Petrocellis L
Curr Pharm Des; 2000 Sep; 6(13):1361-80. PubMed ID: 10903398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
